The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
The 23rd International AIDS Conference (AIDS 2020 Virtual) kicked-off with a clear message from UNAIDS to accelerate efforts to end AIDS and not be derailed by COVID-19.
On International Safe Abortion Day (28 September), we give an overview of the link between HIV and abortion and the need for broader sexual reproductive health rights for women.
Scientists are hesitant to declare that there is no risk of HIV transmission during breastfeeding by mothers with an undetectable viral load, as they have done for sexual transmission. We talk through why it’s contentious.
In their first treatment update since 2016, the World Health Organization (WHO) adopts a ‘treat all’ approach for hepatitis C, guided by the success of the HIV treatment experience.
Dolutegravir’s first bump in the road to global roll-out begs larger questions around women’s rights and access to contraceptives at the International AIDS Conference (AIDS 2018).
Interim clinical trial results offer hope to people living with hepatitis C who stand to benefit from reduced price treatment, including the 2.3 million people who have HIV co-infection.
The 2020 goal of reaching 120 million additional girls and young women with modern contraceptives is likely to be missed, despite millions of new users.
As HIV drug resistance increases in low- and middle-income countries, getting people onto antiretroviral treatment means little in the long run if treatment programming is not also strengthened.
The President’s Emergency Plan for AIDS Relief (PEPFAR) is to accelerate efforts in just 13 countries under its news strategy. But critics say this narrowed focus could lead to a resurgence of the HIV epidemic.
A BMJ international panel made up of women living with HIV, specialist doctors, and general practitioners recommends non-tenofovir based treatment regimes for pregnant women living with HIV.
Savings would be ‘small and transient’ – raising significant ethical and efficacy concerns about the benefit of US budget cuts for HIV programming abroad.